How Testosterone Cypionate Affects PSA Levels

Why Testosterone Cypionate Raises PSA

PSA is a serine protease produced almost exclusively by prostate epithelial cells, and its gene promoter contains androgen-response elements that respond directly to dihydrotestosterone (DHT). When testosterone cypionate is injected intramuscularly, circulating testosterone rises, and 5-alpha reductase in prostate tissue converts a fraction of that testosterone to DHT. DHT binds the androgen receptor with roughly five times the affinity of testosterone itself, upregulating PSA gene transcription and increasing the protein's secretion into the bloodstream 1.

This is basic prostate physiology, not pathology. Hypogonadal men often have artificially low PSA readings because their prostates are under-stimulated. Restoring testosterone to the mid-normal range (400 to 700 ng/dL) simply returns PSA output to what it would be in a eugonadal man of the same age. The Endocrine Society's 2018 clinical practice guideline notes that the expected PSA rise on TRT is modest and should not, by itself, trigger a biopsy 2.

A key distinction: PSA velocity matters more than a single absolute value. A man whose PSA goes from 0.8 to 1.2 ng/mL after starting TRT is following the expected trajectory. A man whose PSA jumps from 0.8 to 3.5 ng/mL in six months is not.

How Much Does PSA Rise? Data From the T-Trials

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older with testosterone below 275 ng/dL, provide the best controlled data on TRT's effect on PSA. Men randomized to daily transdermal testosterone gel saw a median PSA increase of 0.55 ng/mL at 12 months, compared with essentially no change in the placebo group 1. The 95th percentile PSA rise was approximately 1.2 ng/mL.

Injectable testosterone cypionate, dosed at 100 to 200 mg every 1 to 2 weeks, produces higher peak testosterone levels than gels. Peak-to-trough swings can push serum testosterone above 1 to 000 ng/dL in the first 48 hours after injection. Despite these pharmacokinetic differences, PSA responses in observational registries of injectable TRT closely mirror those from the gel-based TTrials. A 2019 meta-analysis of 15 RCTs (total N = 2,768) found a pooled mean PSA increase of 0.49 ng/mL (95% CI 0.32 to 0.66) at 12 months regardless of formulation 3.

The increase is not linear. Most of the rise happens in the first 3 to 6 months, then PSA plateaus. By month 24, the trajectory is flat in the vast majority of patients. A persistent upward slope beyond 12 months is atypical and deserves investigation.

The Prostate Cancer Question

For decades, clinicians avoided prescribing testosterone to older men partly because of the "androgen hypothesis," the idea that higher testosterone drives prostate cancer. Large-scale evidence has weakened this concern considerably.

The TRAVERSE trial (N = 5,204), a cardiovascular safety trial of transdermal testosterone in men aged 45 to 80, tracked prostate cancer as a prespecified secondary endpoint. At a median follow-up of 33 months, prostate cancer incidence was 0.19 events per 100 person-years in the testosterone arm versus 0.12 in the placebo arm, a difference that was not statistically significant (hazard ratio 1.07; 95% CI 0.60 to 1.90) 4.

Dr. Shalender Bhasin, principal investigator of TRAVERSE and professor of medicine at Harvard Medical School, stated: "These data should provide reassurance that testosterone therapy, when appropriately prescribed and monitored, does not meaningfully increase the short- to intermediate-term risk of prostate cancer" 4.

These findings align with the Endocrine Society guideline, which states that "there is no convincing evidence that testosterone therapy increases the risk of prostate cancer" but emphasizes the need for ongoing PSA surveillance 2.

One critical caveat remains. TRT is absolutely contraindicated in men with known metastatic prostate cancer. The data on TRT after curative treatment for localized prostate cancer are limited, though small case series suggest it may be safe in carefully selected men under close urologic surveillance 5.

Baseline PSA: What to Check Before Starting TRT

Every man should have a documented PSA level before the first injection of testosterone cypionate. The American Urological Association (AUA) and the Endocrine Society both recommend a pre-treatment PSA along with a digital rectal exam (DRE) in men over 40 2.

A baseline PSA above 4.0 ng/mL (or above 3.0 ng/mL in men under 60) warrants a urology referral before initiating TRT. This threshold exists because TRT will raise PSA further, making it harder to interpret future changes without a clean starting point.

The baseline also serves as the reference for calculating PSA velocity. Without it, a PSA of 2.8 ng/mL drawn six months into therapy is uninterpretable. Was it 2.5 before? Or 0.9? The clinical response to these two scenarios is completely different.

Additional pre-treatment labs should include a complete blood count (hematocrit in particular, since TRT stimulates erythropoiesis), a lipid panel, and a hepatic function panel. The hematocrit check is especially relevant because polycythemia is the most common dose-limiting adverse effect of injectable testosterone cypionate 2.

PSA Monitoring Schedule on Testosterone Cypionate

The Endocrine Society guideline recommends PSA measurement at 3 to 6 months after starting TRT, again at 12 months, and then annually thereafter 2. The AUA endorses a similar cadence.

Here is a practical monitoring protocol for injectable testosterone cypionate:

Month 0 (baseline): PSA, DRE (men over 40), total testosterone, free testosterone, hematocrit, lipid panel.

Months 3 to 6: Repeat PSA, total testosterone (drawn at trough, meaning the morning before the next scheduled injection), and hematocrit. The 3-to-6-month check catches the early PSA surge and confirms the patient's testosterone level is in the target range of 400 to 700 ng/dL.

Month 12: Repeat PSA, testosterone, hematocrit, lipid panel. Compare PSA to baseline. An increase of 0.3 to 0.5 ng/mL is expected. An increase exceeding 1.4 ng/mL per year, or a total PSA above 4.0 ng/mL, should trigger urology referral 6.

Annually thereafter: PSA, testosterone, hematocrit. DRE per shared decision-making with the patient.

The 1.4 ng/mL per year velocity threshold comes from a Johns Hopkins longitudinal study of the Baltimore Longitudinal Study of Aging, which found that this rate of PSA rise was the most specific single predictor of lethal prostate cancer, outperforming absolute PSA cutoffs 6.

What to Do When PSA Rises More Than Expected

A PSA rise that exceeds the expected range (roughly above 1.0 ng/mL in 12 months or any total PSA above 4.0 ng/mL) requires a structured response, not panic.

Step 1: Repeat the test. PSA can be transiently elevated by ejaculation within 24 hours before the draw, vigorous cycling, urinary tract infection, or prostatitis. Confirm the elevation on a second draw taken at least 4 weeks later, with the patient abstaining from ejaculation for 48 hours before the test.

Step 2: Check the testosterone level. Supratherapeutic testosterone (above 1 to 000 ng/dL at trough) can drive a larger PSA response. Dose reduction may normalize PSA without discontinuing TRT entirely.

Step 3: Refer to urology. If the repeat PSA confirms the elevation, urology referral for consideration of multiparametric MRI (mpMRI) and possible targeted biopsy is appropriate. The American Cancer Society notes that mpMRI has significantly reduced unnecessary biopsies by identifying clinically significant lesions with a negative predictive value exceeding 90% 7.

Step 4: Hold TRT pending workup. Most guidelines recommend holding testosterone until the urologic evaluation is complete. PSA will begin to decline within 2 to 4 weeks of discontinuation if the rise was purely androgen-driven.

Dr. Abraham Morgentaler, associate clinical professor of urology at Harvard Medical School and a leading researcher on testosterone and prostate safety, has written: "The fear of testosterone causing prostate cancer has been one of the great myths in medicine. The real risk is not monitoring appropriately" 8.

PSA Differences Between Testosterone Formulations

Testosterone cypionate is an intramuscular ester with a half-life of approximately 8 days. Its pharmacokinetic profile produces pronounced peak-to-trough fluctuations. By contrast, transdermal gels and patches produce steadier serum levels, and subcutaneous testosterone pellets release hormone over 3 to 6 months.

Despite these pharmacokinetic differences, the net PSA effect is remarkably consistent across formulations. The 2019 meta-analysis by Cui and colleagues found no statistically significant difference in PSA change between injectable, transdermal, and pellet testosterone at 12 months 3. The prostate integrates androgen exposure over weeks to months, smoothing out the peaks that injectable users experience in the first 48 hours post-injection.

One practical implication: PSA drawn at the testosterone peak (1 to 2 days post-injection) and at the trough (the day before the next injection) should be nearly identical because PSA clearance from blood has a half-life of 2 to 3 days, long enough to buffer short-term hormonal spikes. Standardizing the draw to trough timing is still good practice for testosterone measurement consistency, but the PSA value itself is stable regardless of injection timing within the cycle.

Age, Ethnicity, and Prostate Volume: Factors That Modify PSA Response

Not every man on testosterone cypionate will see the same PSA change. Several patient-specific variables influence the magnitude of the response.

Age. Older men tend to have larger prostates and higher baseline PSA. Their absolute PSA increase on TRT may be slightly larger, though the percentage change is similar to younger men. The T-Trials cohort (age 65+) showed a median rise of 0.55 ng/mL 1, while younger cohorts in other studies have shown rises of 0.3 to 0.4 ng/mL.

Prostate volume. A larger gland has more epithelial cells producing PSA. Men with benign prostatic hyperplasia (BPH) and prostate volumes above 40 mL may see PSA increases at the upper end of the expected range. Adding a 5-alpha reductase inhibitor such as finasteride or dutasteride can blunt the PSA rise by approximately 50%, but this must be factored into future PSA interpretation 9.

Ethnicity. African American men have higher age-adjusted PSA levels at baseline and a higher incidence of prostate cancer. The NCCN recommends that these patients discuss PSA screening beginning at age 40. When these men start TRT, the same monitoring thresholds apply, but the pre-existing statistical risk means that urology referral should carry a lower threshold for biopsy 10.

5-alpha reductase inhibitor use. Men taking finasteride or dutasteride concurrently with TRT will have a suppressed PSA. The standard correction is to double the measured PSA value to estimate the "true" level. Any PSA rise in a man on both TRT and a 5ARI should be taken seriously, as the inhibitor masks the normal androgen-driven increase 9.

The Bottom Line on TRT and PSA Safety

Testosterone cypionate will raise PSA. The expected magnitude is 0.3 to 0.5 ng/mL at 12 months, with stabilization by 24 months. This rise does not indicate cancer. RCTs enrolling over 6,000 men have found no significant increase in prostate cancer incidence with TRT lasting up to 3 years. The clinical priority is not avoiding the PSA rise but tracking it correctly: baseline PSA before the first injection, repeat at 3 to 6 months, at 12 months, and annually, with urology referral for any velocity exceeding 1.4 ng/mL per year or total PSA above 4.0 ng/mL 2.